Highlights: US Naval Medical Research Command campylobacter clinical program completes in-patient phase Manufacture of IMM-529 drug substance to support the Pre-IND information package has been.
Globally integrated biopharmaceutical company Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has initiated the second cohort of a clinical trial aimed at assessing the.
Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced.
Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced the second
Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has enrolled its first cohort of 30 participants into the Travelan® clinical trial to evaluate its efficacy to prevent.